The TALZENNA XTANDI approval announced by Pfizer Inc. (NYSE: PFE) on October 26, 2026 expands the U.S. use of TALZENNA (talazoparib) with XTANDI (enzalutamide) to men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer who have homologous recombination repair (HRR) gene mutations. The U.S. Food and Drug Administration (FDA) decision covers both BRCA and non-BRCA mutations. Pfizer notes that mAPMN/S disease is also known as metastatic hormone-sensitive prostate cancer (mHSPC).
TALZENNA is an oral poly ADP-ribose polymerase (PARP) inhibitor, and XTANDI is an androgen receptor pathway inhibitor (ARPI). With the TALZENNA XTANDI approval, Pfizer says the pairing is now available in an earlier line of therapy, offering an opportunity to delay disease progression at a critical stage when more patients may experience greater benefit.
The decision is based on the pivotal Phase 3 TALAPRO-3 study, which showed an estimated 52% reduction in the risk of radiographic progression or death. The combination was first approved in the U.S. in 2023 for metastatic androgen pathway modulation-resistant (mAPMR) disease, also called HRR-mutated metastatic castration-resistant prostate cancer (mCRPC). The application to expand the indication was reviewed under FDA Priority Review. For wider context, see our coverage of Pfizer oncology news [INT-1].
What the TALZENNA XTANDI Approval Means for HRR-Mutated Metastatic Prostate Cancer
Pfizer describes the TALZENNA XTANDI approval as building on the combination’s established role as a standard-of-care option for men with advanced prostate cancer. Aamir Malik, Executive Vice President and Chief U.S. Commercial Officer at Pfizer, said moving the targeted therapy into the androgen pathway modulation-naïve or -sensitive setting reflects the company’s commitment to men with HRR-mutated metastatic prostate cancer and offers a new option where it may have a greater impact on delaying progression.
Neeraj Agarwal, M.D., FASCO, co-director of the Prostate Cancer Program at Harvard Cancer Consortium, faculty medical oncologist at Dana-Farber Cancer Institute and global lead investigator for TALAPRO-3, called the decision a critical advancement for patients with newly diagnosed metastatic prostate cancer and HRR gene mutations. He said these patients face more aggressive disease, a worse prognosis and limited treatment options, and that consistent benefit across BRCA and non-BRCA mutations reinforces biomarker testing at the time of diagnosis [INT-2].
Pfizer states that approximately 25% of patients with mAPMN/S prostate cancer (mHSPC) harbor HRR gene mutations, a figure it attributes to published literature. The disease has spread beyond the prostate but remains sensitive to androgen deprivation therapy. Because the U.S. indication requires HRR mutations detected by an FDA-authorized test, the TALZENNA XTANDI approval depends directly on molecular testing before treatment.
Approval Snapshot
| Parameter | Detail |
|---|---|
| Company | Pfizer Inc. (NYSE: PFE) |
| Products | TALZENNA (talazoparib) plus XTANDI (enzalutamide) |
| Regulator | U.S. Food and Drug Administration (FDA) |
| Announcement date | October 26, 2026 |
| New indication | HRR gene-mutated mAPMN/S (mHSPC) prostate cancer, BRCA and non-BRCA |
| Prior U.S. approval | June 2023, HRR gene-mutated mAPMR prostate cancer (HRRm mCRPC) |
| Review pathway | FDA Priority Review; Project Orbis |
| Testing requirement | HRR mutations detected by an FDA-authorized test |
TALAPRO-3 Data Behind the TALZENNA XTANDI Approval
TALAPRO-3 (NCT04821622) [EXT-1] is a multicenter, randomized, double-blind, placebo-controlled study that enrolled 599 patients with mAPMN/S prostate cancer who had received three months or less of androgen deprivation therapy (chemical or surgical), with or without an approved ARPI in that setting. Sites were located in the U.S., Canada, Europe, South America and the Asia-Pacific region.
Patients were randomized to receive TALZENNA 0.5 mg/day plus XTANDI 160 mg/day, or placebo plus XTANDI 160 mg/day. The primary endpoint is investigator-assessed radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic progression in soft tissue per RECIST 1.1, or in bone per PCWG3 criteria, or death, whichever occurs first.
In patients with HRR gene mutations, TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI (hazard ratio 0.48; 95% confidence interval 0.36–0.65; p < 0.0001). An estimated 77% of patients remained progression-free at three years, and benefit was consistent across BRCA and non-BRCA subgroups. These figures are the clinical core of the TALZENNA XTANDI approval. The data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine [EXT-2].
TALAPRO-3 Design and Results
| TALAPRO-3 Metric | Reported Value |
|---|---|
| ClinicalTrials.gov ID | NCT04821622 |
| Design | Multicenter, randomized, double-blind, placebo-controlled Phase 3 |
| Patients enrolled | 599 |
| Treatment arm | TALZENNA 0.5 mg/day + XTANDI 160 mg/day |
| Control arm | Placebo + XTANDI 160 mg/day |
| Primary endpoint | Investigator-assessed rPFS |
| rPFS risk reduction | 52% (HR 0.48; 95% CI 0.36–0.65; p < 0.0001) |
| Progression-free at 3 years | Estimated 77% |
| Overall survival result | Not disclosed (key secondary endpoint) |
ALZENNA XTANDI Approval Safety Profile and Prescribing Information
Pfizer states the safety profile was consistent with the known profiles of each agent, and no new safety signals were identified. The most common treatment-emergent adverse events (TEAEs) in the combination group were anemia, fatigue, decreased neutrophil count and asthenia. Anemia was also the most common grade 3 or higher TEAE, reported by 51% of the combination group and 3% of the control group. Five percent of patients discontinued TALZENNA because of anemia.
According to Pfizer, TEAEs were generally manageable with dose modifications and supportive care as needed. The TALZENNA label carries warnings for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), myelosuppression and embryo-fetal toxicity. Among 1,096 patients treated with TALZENNA alone or with enzalutamide, cumulative MDS/AML incidence was approximately 1%, including 0.6% with fatal outcomes, and the label advises monthly blood count monitoring.
In the pooled safety population of 810 prostate cancer patients, the most common adverse reactions of 20% or more included decreased hemoglobin (86%), decreased neutrophils (68%), decreased lymphocytes (62%), decreased platelets (54%) and fatigue (48%). Clinicians and patients should review the Full Prescribing Information [EXT-3] and our TALZENNA drug profile [INT-3] when weighing the TALZENNA XTANDI approval.
Safety Data
| Safety Item | Reported Value |
|---|---|
| Most common TEAEs (combination arm) | Anemia, fatigue, decreased neutrophil count, asthenia |
| Grade 3 or higher anemia (TALAPRO-3) | 51% combination vs. 3% control |
| TALZENNA discontinuation due to anemia | 5% |
| Grade 3 or higher anemia / neutropenia / thrombocytopenia (label, with enzalutamide) | 49% / 19% / 9% |
| Red blood cell transfusion required (label) | 41%, including 25% needing more than one |
| MDS/AML cumulative incidence (1,096 patients) | Approximately 1%; 0.6% fatal |
| Pooled safety population (prostate cancer) | 810 patients |
| New safety signals | None identified |
Global Regulatory Outlook After the TALZENNA XTANDI Approval
The FDA conducted its review under Project Orbis [EXT-4], an Oncology Center of Excellence initiative that provides a framework for concurrent submission and review of oncology drugs among international partners. An application is also under review by the European Medicines Agency (EMA), with additional global filings planned or underway. The European Commission approved TALZENNA with XTANDI in January 2024 for adults with mCRPC in whom chemotherapy is not clinically indicated, and the combination is approved in more than 60 countries, with indications varying by country.
XTANDI has received approvals for metastatic hormone-sensitive, metastatic castration-resistant, non-metastatic castration-resistant and non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence in more than 80 countries. Pfizer says over 1.5 million patients have been treated with XTANDI worldwide, and the drug is jointly developed and commercialized with Astellas in the United States. TALZENNA was initially approved as a single agent for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.
Pfizer frames the milestone as part of a 20-year commitment to genitourinary cancers and to moving precision medicines into earlier disease stages. The release contains forward-looking statements, including uncertainty over whether TALAPRO-3 will meet its overall survival endpoint and over the commercial success of the combination. Pricing and launch timing are not disclosed. Investors can verify risk disclosures in Pfizer’s SEC filings [EXT-5], and the full announcement is available on Pfizer’s investor site as the primary source for the TALZENNA XTANDI approval [INT-4].
